Last Update 25 Mar 26

PACB: Rare Disease Genomics Collaborations Will Drive Long Term Upside Potential

Narrative Update on Pacific Biosciences of California

Analysts trimmed their PacBio price target from $2.00 to $1.50, citing a tougher near term setup and the possibility of a consumables demand pause in 2026 as customers adjust to competitive sequencing launches and prepare for SPRQ NX.

Analyst Commentary

Recent commentary around Pacific Biosciences of California has turned more cautious, with the latest published view moving the rating to Underweight and setting a US$1.50 price target, down from US$2. The focus is squarely on execution risks over the next couple of years as the sequencing market evolves and customers plan for SPRQ NX.

Bearish Takeaways

Bearish analysts describe a tough near term setup for the shares. They highlight that competitive launches across the sequencing market could pressure PacBio's ability to grow consumables usage at the pace some investors might expect.
The revised US$1.50 price target, compared with the prior US$2 level, reflects concern that execution on consumables growth and system utilization may fall short of earlier expectations. This feeds directly into a lower valuation framework.
Analysts see potential for a pause in consumables demand in the first half of 2026 as customers slow research activity and adjust spending ahead of SPRQ NX. This could weigh on revenue visibility and create a period of weaker reported performance.
The move from an Equal Weight to an Underweight rating signals that, in the view of bearish analysts, risk around near term growth and competitive pressure currently outweighs the upside they see at the current share price.

What's in the News

Basecamp Research selected PacBio HiFi sequencing on the Revio system for the Trillion Gene Atlas, a project targeting about 100,000 deeply sequenced environmental and host associated metagenomic samples from more than 31 countries across 5 continents, using SPRQ Nx chemistry for efficiency and cost effectiveness (Client Announcements).
PacBio is supporting the Trillion Gene Atlas with production scale workflows refined in earlier large programs such as the All of Us Research Program, the Estonia Biobank, and the Darwin Tree of Life. This positions Revio with SPRQ Nx as a platform for large scale, high fidelity long read sequencing used in biological foundation models and AI driven design (Client Announcements).
A collaboration with DNAstack under the HiFi Solves Global Consortium is creating a global federated dataset of HiFi whole genome sequencing data, connecting or committing more than 10,000 HiFi genomes from nearly 30 institutions across 15 countries for rare disease research while keeping data under institutional control (Strategic Alliances).
UW Medicine and Seattle Children’s researchers are using PacBio HiFi whole genome sequencing as a first line tool to investigate Sudden Unexplained Death in Childhood, with each child and both parents sequenced to capture complex variants such as structural variants and tandem repeats. The team is joining the HiFi Solves Global Consortium (Product Related Announcements).
PacBio plans a collaboration with the n Lorem Foundation and EspeRare to apply long read whole genome sequencing to the design and molecular characterization of individualized antisense oligonucleotide therapies for ultra rare genetic diseases. The collaboration includes donated sequencing reagents and scientific support from PacBio (Client Announcements).

Valuation Changes

Fair Value: $2.43 per share is unchanged, and the updated model keeps the same implied level as before.
Discount Rate: The discount rate has edged lower from 11.63% to 11.57%, indicating a slightly lower required return in the latest assumptions.
Revenue Growth: The revenue growth assumption remains effectively steady at about 12.00%, with only a very small numerical adjustment.
Net Profit Margin: The net profit margin is essentially flat, moving marginally from 15.51% to 15.52% in the updated model.
Future P/E: The future P/E multiple is broadly stable, moving slightly from 29.75x to 29.68x, indicating minimal change in the valuation multiple being used.

4 views

Key Takeaways

Expanding adoption in global genomics projects and clinical labs is boosting recurring revenue streams, margin stability, and market diversification.
Technical innovation and cost discipline are strengthening competitive leadership, reducing expenses, and supporting long-term earnings growth and sustainability.
Ongoing dependence on academic funding, international risks, losses, competitive pressures, and concentrated revenue sources threaten sustainable growth and increase financial uncertainty.

Catalysts

About Pacific Biosciences of California

Designs, develops, and manufactures sequencing solution to resolve genetically complex problems.What are the underlying business or industry changes driving this perspective?

The growing number of national-scale population genomics and multi-omic initiatives globally-many adopting PacBio's long-read HiFi technology (e.g., 1,000 Genomes Long-Read Project, Southeast Asia and Nordic national programs)-positions PacBio to capture expanding large-volume projects, which should materially increase future revenues and drive recurring consumables demand.
Increasing utilization and adoption of PacBio's platforms across clinical, diagnostic, and hospital labs (with 1/3 of recent Revio placements to clinical settings, and clinical consumables now representing 15% and rising) supports a shift toward more stable, higher recurring consumable/service revenues and improved gross margins as clinical use grows.
Ongoing innovation-including launches of SPRQ chemistry (33% throughput gain, lower sample costs), PureTarget panels, and upcoming multi-use SMRT Cell (enabling reuse, lower cost per genome, and higher gross margin)-provides technical leadership in accuracy, cost, and workflow, expanding addressable markets and supporting margin expansion and earnings growth.
Strong momentum in international markets (APAC +53%, EMEA +35% YoY), driven by hospital, clinical, and research customer wins and broader access enabled by the lower-cost Vega system, helps diversify revenue streams and offsets U.S. funding headwinds, contributing to overall growth and improved revenue predictability.
Cost discipline measures (headcount reductions, restructuring, R&D focus) and scale-driven unit cost improvements (higher SMRT Cell yields, production-rate Vega systems) are driving non-GAAP operating expense and cash burn reductions, with a credible path to positive cash flow by 2027-supporting sustainability of future net margins and earnings.

Pacific Biosciences of California Earnings and Revenue Growth

Pacific Biosciences of California Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Pacific Biosciences of California's revenue will grow by 12.0% annually over the next 3 years.
Analysts are not forecasting that Pacific Biosciences of California will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Pacific Biosciences of California's profit margin will increase from -341.5% to the average US Life Sciences industry of 15.5% in 3 years.
If Pacific Biosciences of California's profit margin were to converge on the industry average, you could expect earnings to reach $34.9 million (and earnings per share of $0.11) by about March 2029, up from -$546.4 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 29.8x on those 2029 earnings, up from -0.8x today. This future PE is lower than the current PE for the US Life Sciences industry at 35.8x.
Analysts expect the number of shares outstanding to grow by 0.64% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 11.57%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Persistent dependence on academic and government funding, particularly in the U.S. market, exposes Pacific Biosciences to ongoing revenue pressure and significant uncertainty in instrument sales as NIH and research spending remain constrained, limiting growth and potentially resulting in volatile quarterly results.
Despite international growth, exposure to geopolitical volatility and trade policy uncertainty in key regions like China creates ongoing risks to global supply chains and customer demand, potentially raising costs of goods sold (COGS), compressing gross margins, and threatening future expansion in high-growth APAC markets.
The company continues to report significant non-GAAP net losses and ongoing negative cash flow, requiring them to carefully manage cash reserves and control operating expenses; failure to achieve profitability or positive cash flow by 2027 could necessitate dilutive equity raises, adversely affecting earnings per share and long-term shareholder value.
The rapid pace of innovation and competitive pressure from both established players and new entrants in the sequencing market may drive further price reductions and market share battles, potentially eroding Pacific Biosciences' pricing power, constraining gross and net margins, and challenging their ability to maintain technical differentiation.
Heavy reliance on large population-scale genomic and clinical research initiatives for future revenue growth introduces concentration risk; any slowdown or shift in funding priorities for these projects-caused by macroeconomic, regulatory, or institutional factors-could disrupt the company's trajectory toward higher recurring revenue and more predictable earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $2.43 for Pacific Biosciences of California based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $3.0, and the most bearish reporting a price target of just $1.5.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $224.8 million, earnings will come to $34.9 million, and it would be trading on a PE ratio of 29.8x, assuming you use a discount rate of 11.6%.
Given the current share price of $1.39, the analyst price target of $2.43 is 42.8% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Pacific Biosciences of California?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Long-read Sequencing And Genomics Trends Will Expand Market Potential